Imaging is pivotal in chest disease diagnosis as the chest wall renders the heart and lungs inaccessible to physical examination and chest disease symptoms are very nonspecific (eg, cough, shortness of breath). Very early in the development of medical x-ray technology, it was recognized that the chest radiograph could provide essential diagnostic information (eg, pneumonia, lung masses, pneumothorax, cardiac failure). For this reason there was rapid uptake of chest radiography, and it continues to be highly relevant, over 100 years later. However, the chest radiograph has substantial limitations as it only provides a single, 2-dimensional view of the complex 3-dimensional structure of the chest. Even with the addition of the lateral view, detection of small lung nodules may substantially vary amongst expert radiologists. Thus, while lung masses greater than 30 mm in diameter are reliably identified, it has been shown that depending on location, lung nodules may be missed with a median diameter of 19 mm [1] .
The strongest prognostic indicator of lung nodule malignant potential is size. Therefore, the detection of small lung cancers is strongly correlated with improved 5-year survival. In the hope of improving lung cancer survival, randomized clinical trials of screening chest radiography were performed in the 1970s. However, these trials failed to show a significant effect on lung cancer mortality [2] . Failure of these trials to impact mortality was believed by some to be secondary to poor imaging of small nodules using plain radiography. Poor imaging also limited our understanding of the link between small nodules and lung cancer.
The introduction of computed tomography (CT) initially revolutionized brain diagnosis. With further technical advances, similar advances were realized in the chest. In comparison to the planar chest radiograph, CT images are cross sectional views of the chest. The cross-sectional perspective is provided by the 900-1500 views that are combined using a computer-driven reconstruction algorithm. Initially chest CT was limited by acquisition times measured in minutes and centimeter thick sections, making it difficult to see nodules smaller than 10 mm. Chest CT was greatly improved by the introduction of helical acquisition (1991) and multidetector row technology (2000). This allowed contiguous thin section images (<3 mm) throughout the chest within a single breath hold at low (<1.5 mSv) radiation dose. For the first time small nodules (<3 mm) could be reliably visualized and longitudinally followed with acceptable cumulative radiation dose. The wide dissemination of CT scanners and expanded chest CT clinical indications provided a large amount of anecdotal information on incidentally found small lung cancers. This facilitated the application of low-dose CT (LDCT) to lung cancer screening [3] . Baseline and follow-up scans in these trials generated large quantities of longitudinal data that provided a more complete understanding of lung nodules and their relationship to lung cancer [4] .
Lung nodules are recognized as well circumscribed soft tissue (w100 HU) aggregates less than 30 mm in diameter within the lung parenchyma. They are easily visualized using LDCT since they displace very low-density air (À1000 HU). Accurate separation of the soft tissue component into fibrotic, inflammatory, hemorrhagic, or neoplastic etiology cannot be reliably achieved using any current CT method (nonecontrast enhanced, contrast enhanced, dual energy). An infective or hemorrhagic etiology can often be inferred based on clinical setting (eg, fever, sputum production, hemoptysis) and nodule morphology (clustered nodules). The separation of benign from neoplastic nodules can be more challenging. While neoplastic nodules tend to have morphologic features including larger size (diameter, volume), spiculated margins, and upper lobe location, these features are not reliable enough to guide clinical management. The most reliable differentiating feature of benign from neoplastic nodules is growth, with neoplastic nodules demonstrating growth with doubling time from 50-400 days. Intravenous contrast enhancement features of neoplastic and inflammatory nodules have been extensively investigated, but this has not proved adequately reliable clinically. Serial low-dose nonecontrast-enhanced LDCT scans are the most commonly used imaging technique to separate these two nodule subtypes, relying on the detection of growth. Definitive separation of neoplastic from benign nodules requires biopsy, but this can also be inaccurate based on sampling error especially for smaller nodules [5] . Excision biopsy, with or without guidance, is the definitive maneuver to separate these nodule subtypes [6] . For small nodules, biopsy is usually done after a period of observation to establish growth.
Nodules are categorized according to their density: solid, part-solid, and non-solid. Solid nodules have uniform soft tissue density. Non-solid show increased density over surrounding air filled lung but lower density than pulmonary vasculature. Part-solid nodules contain both solid and nonsolid components. Solid and non-solid nodules are much more common than part-solid nodules. Part-solid nodules have a higher malignant potential than either solid or non-solid nodules. There is anecdotal evidence that non-solid nodules evolve into part-solid nodules, with the solid component representing malignant transformation. Complete understanding of this process will require further investigation.
The requirement for serial imaging raises questions about the frequency and duration of repeat CT scanning. The most commonly used guidelines for serial follow-up of lung nodules are based on expert opinion from the Fleischner Society [7] . These criteria are based on clinical risk, primarily arising from smoking history and nodule average diameter in the transverse plane. New information regarding nodule malignant potential has recently become available from serial CT scans obtained in lung cancer screening trials. A multivariate model using baseline nodule features as well as clinical features such as gender, family history of lung cancer, presence of emphysema, and nodule count was determined in the Pan-Canadian lung cancer screening cohort and generated the parameters for a nodule malignancy risk calculator [4] . This risk calculator model was then applied to baseline scans in a second cohort where it demonstrated a high accuracy of >93% even for nodules 10 mm [4] . This nodule malignancy risk calculator is available for free on the internet (http://www.brocku.ca/lungcancer-risk-calculator) and as an iPad or iPhone application. The calculator provides an evidence-based approach to guide management of screen detected lung nodules in high-risk smokers [8] . With large CT screening clinical trial data becoming available such as from the National Lung Screening Trial [9] , the action threshold can be further refined. Advances in computer vision technology that can automatically identify and characterize lung nodules as well as quantitative analysis of the adjacent lung parenchyma, vessels, and airways may provide additional valuable information on lung cancer risk in addition to improving the consistency and quality of scan interpretation [10, 11] .
The recommendation by the U.S. Preventive Services Task Force to screen high-risk smokers with LDCT that can potentially reduce lung-cancer mortality by 20% [12] and the recent proposed decision by the Centers for Medicare and Medicaid Services to fund LDCT screening under the Medicare program [13] make it likely that LDCT screening will be implemented at the population level in the United States in 2015. It is expected that other countries will follow suit. Large numbers of lung nodules will be found on screening LDCT. It is imperative to have evidence-based national and international guidelines to manage screen detected lung nodules to optimize the cost-effectiveness of screening programs. The incremental cost-effectiveness ratio can be substantially higher or lower depending on the number of follow-up CT scans per positive screening examination compared to the National Lung Screening Trial [14] . A probabilistic approach to define what constitutes a positive screen could substantially decrease the number of follow-up CTs obtained and would be a step in the right direction [8] .
In summary, advances in CT scanner technology have facilitated improvements in our knowledge of the natural history of lung cancer and allowed the development of a lung cancer screening strategy that has been shown to reduce lung cancer mortality.
